Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 6/20 | 0.48 |
| ▸ | PTK2B | Q14289 | 4/20 | 0.48 |
| ▸ | SYK | P43405 | 4/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 3/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6258964 | 0.91 | SYK (0.47) | EGFRPTK2PTK2BSYKKCNH2 | |
| SCHEMBL6260739 | 0.89 | EGFR (0.49) | EGFRPTK2PTK2BSYKNPC1 | |
| SCHEMBL6260019 | 0.85 | PTK2 (0.52) | EGFRPTK2PTK2BSYKKDR | |
| SCHEMBL12185449 | 0.84 | EGFR (0.54) | EGFRSYKKDRIGF1RJAK2 | |
| SCHEMBL6209413 | 0.84 | QPCT (0.45) | PTK2PTK2BSYKKCNH2KDM4E | |
| SCHEMBL6259622 | 0.84 | PTK2 (0.67) | EGFRPTK2PTK2BSYKKDR | |
| SCHEMBL6210739 | 0.83 | SYK (0.50) | PTK2PTK2BSYKKCNH2KDM4E | |
| SCHEMBL6216051 | 0.82 | AURKA (0.61) | PTK2PTK2BSYKKCNH2KDM4E | |
| SCHEMBL6213157 | 0.81 | PTK2 (0.61) | EGFRPTK2PTK2BSYKKDR | |
| SCHEMBL879560 | 0.81 | EGFR (0.69) | EGFRSYKNPC1RAB9AKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040220177-A1 | Compound for the treatment of abnormal cell growth | PFIZER INC | 2004-11-04 | — | — | US | claimed |
| EP-1578732-A2 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Pfizer Products Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20040220177-A1 | Compound for the treatment of abnormal cell growth | PFIZER INC | 2004-11-04 | — | — | US | disclosed |
| WO-2004056786-A2 | PYRIMIDINE DERIVATES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220177-A1 | Compound for the treatment of abnormal cell growth | CCNA1, CCNB1, CCNT1 | EGFR 68/4885PTK2 3004/4885PTK2B 1941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.